{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:27:16Z","timestamp":1763389636923,"version":"3.45.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007161","name":"Boston University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jtct.2022.08.007","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T13:12:43Z","timestamp":1660309963000},"page":"761.e1-761.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-2703","authenticated-orcid":false,"given":"Hamza","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-9129","authenticated-orcid":false,"given":"Grace","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Brauneis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Quillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-4528","authenticated-orcid":false,"given":"J. Mark","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-0667","authenticated-orcid":false,"given":"Camille Vanessa","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2022.08.007_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtct.2022.08.007_bib0002","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.08.007_bib0003","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtct.2022.08.007_bib0004","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.08.007_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2022.08.007_bib0006","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.08.007_bib0007","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0008","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0009","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2012-09-457341","article-title":"High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center","volume":"120","author":"Tsai","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2022.08.007_bib0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41375-020-1006-7","article-title":"Organ responses after high-dose melphalan and stem cell transplantation in AL amyloidosis","volume":"35","author":"Szalat","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.08.007_bib0011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.14889","article-title":"A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time","volume":"179","author":"Sanchorawala","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0012","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report","volume":"51","author":"Gertz","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.08.007_bib0013","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/bmt.2013.98","article-title":"Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115","volume":"48","author":"Sanchorawala","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.007_bib0014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2141.1999.01216.x","article-title":"Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis","volume":"104","author":"Comenzo","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0015","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2006-06-029728","article-title":"Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65","volume":"108","author":"Seldin","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.08.007_bib0016","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.bbmt.2018.06.017","article-title":"Autologous stem cell transplant for immunoglobulin light chain amyloidosis patients aged 70 to 75","volume":"24","author":"Sidiqi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.007_bib0017","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0018","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.16198","article-title":"Establishment of brain natriuretic peptide-based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis","volume":"188","author":"Lilleness","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0020","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.08.007_bib0021","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/bjc.2017.202","article-title":"Geriatric assessment is superior to oncologists' clinical judgement in identifying frailty","volume":"117","author":"Kirkhus","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtct.2022.08.007_bib0022","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival","volume":"52","author":"Tandon","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.007_bib0023","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bmt.1704691","article-title":"Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate","volume":"34","author":"Gertz","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.007_bib0024","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.clml.2021.01.021","article-title":"Clinical characteristics, treatment regimens, and survival in elderly patients with AL amyloidosis","volume":"21","author":"Acevedo","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.08.007_bib0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.08.007_bib0026","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V118.21.2041.2041","article-title":"Infectious complications in patients with AL (immunoglobulin light chain) amyloidosis undergoing treatment with high-dose melphalan and autologous stem-cell transplantation (HDM\/SCT)","volume":"118","author":"Taimur","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.08.007_bib0027","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.007_bib0028","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1704344","article-title":"Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome","volume":"33","author":"Mollee","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.007_bib0029","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.08.007_bib0030","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"Muchtar","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.08.007_bib0031","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.08.007_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:03:51Z","timestamp":1763003031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722015457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2666636722015457"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}